Improved intermediate visual function with new monofocal intraocular lens in combined cataract and vitrectomy surgery for retinal disease.

PURPOSE: To evaluate the usefulness of a newly generated monofocal intraocular lens (IOL) in patients with various retinal diseases who underwent combined cataract and pars plana vitrectomy (PPV) surgery.

METHODS: This prospective observational study included 33 patients with various retinal diseases. Monocular corrected and uncorrected distance visual acuity (BCDVA, UCDVA), uncorrected intermediate visual acuity (UCIVA), uncorrected near visual acuity (UCNVA), and contrast sensitivity were measured and compared with those in 30 age-matched normal controls. Further, UCIVA/UCDVA and UCNVA/UCDVA ratios were calculated.

RESULTS: The mean preoperative BCDVA was 0.94 ± 0.77 logMAR and postoperative BCDVA was 0.14 ± 0.14 logMAR. There was a significant improvement in BCDVA at 3 months follow up. (p < 0.0001) At 3 months after surgery, the ratio of UCIVA to UCDVA was 0.82 ± 0.11 in the patient group, which was not significantly different from the control group. (p = 0.729) The contrast sensitivities of patients were similar to those of 80% of the normal contrast sensitivity.

CONCLUSIONS: Combined cataract and vitrectomy surgery with Eyhance IOL in patients with retinal diseases can benefit from improving intermediate vision without compromising far vision and contrast sensitivity.